Post‐COVID immunity in patients with solid tumor or hematological malignancies treated with SARS‐CoV‐2 monoclonal antibodies

Post‐COVID immunity in patients with solid tumor or hematological malignancies treated with SARS‐CoV‐2 monoclonal antibodies

Abstract Purpose SARS‐CoV‐2 monoclonal antibody (mAB) therapy has effectively treated severe COVID‐19, although how this contributes to protective antiviral immunity in settings of malignancy is poorly defined. Patients and Methods We evaluated the development of post‐infection immunity in five pati...

Full description

Saved in:
Bibliographic Details
Main Authors: Gilberto Sabino‐Santos, Cathryn E. Leggio, Sean M. Litwin, Najia Waheed, Shuangyi Bai, Sinem Ulusan, Anoli Karunathilake, Debra H. Elliott, Ashley R. Smira, Sruti Chandra, Lin Li, Bo Ning, Tony Hu, John S. Schieffelin, Bronwyn M. Gunn, James E. Robinson, Jyotsna Fuloria, Elizabeth B. Norton
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:Immunity, Inflammation and Disease
Subjects:
hematological malignancies
memory immunity
monoclonal antibody therapy
SARS‐CoV‐2
Online Access:https://doi.org/10.1002/iid3.70039
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/iid3.70039

Similar Items